The TRPA1 and TRPV1 receptors are important pharmaceutical targets for antipruritic and analgesic therapy. Obtaining further knowledge on their roles and interrelationship in humans is therefore crucial. Preclinical results are contradictory concerning coexpression and functional interdependency of TRPV1 and TRPA1, but no human evidence exists. This human experimental study investigated whether functional responses from the subpopulation of TRPA1 1 nociceptors could be evoked after defunctionalization of TRPV1
Introduction
A variety of receptors are expressed by cutaneous nociceptors (C and Ad fibers). Key transducers include the transient receptor potential vanilloid 1 (TRPV1) and ankyrin 1 (TRPA1), both of which are members of the TRP ion-channel superfamily. 44 TRPA1 and TRPV1 are activated by various algogens and noxious stimuli, and much G protein-coupled receptor (GPCR)-detected nociceptive and pruriceptive signaling co-opts these channels. In particular, TRPA1 is required for nonhistaminergic itch, as multiple histamineindependent itch transduction pathways involve TRPA1 coactivation. 88 TRPA1 is also involved in pain as well as inflammation of the skin, airways, and gastrointestinal tract, acting both as an inflammatory instigator and a detector of various inflammatory mediators. 19, 67 TRPA1 signalling has been implicated in a diverse range of diseases including migraine, 28 diabetic neuropathy, 47 and atopic dermatitis, where lesional skin areas exhibit highly increased expression. 60, 63 Although capsaicin activates TRPV1, allyl isothiocyanate (AITC), also known as mustard oil, activates TRPA1. 10 TRPV1 is evidently more densely expressed in rodent dorsal root ganglion (DRG) nociceptors than TRPA1, but the 2 receptors do exhibit substantial coexpression. However, it remains unclear whether a functionally significant subpopulation of TRPA1 1 but TRPV1 2 nociceptors exists. After the initial discovery of TRPA1, rodent studies showed an almost complete DRG coexpression of TRPV1 and TRPA1 mRNA. 81 Using calcium imaging in rat trigeminal ganglia, AITC responsiveness was shown in 35% of the neurons, whereas capsaicin exited 55%, including all the AITC-responsive cells. 40 Contrasting these findings, several recent rodent studies using, for example, back-labeling of cutaneous afferents and unbiased single-cell RNA sequencing have suggested that TRPA1 1 nociceptors that do not express TRPV1 are much more common than previously assumed. 36, 50, 56, 82, 85 As such, the expressional patterns of TRP channels in nociceptive DRG neurons and on peripheral nociceptors, and in particular, the functional overlap between TRPA1 and TRPV1 in the nociceptive system of rodents remain unknown. Moreover, despite substantial interspecie differences in somatosensory processing, 22 no attempts have been conducted in human skin to assess whether TRPA1-induced responses are predominantly TRPV1 fiber-dependent.
Because of the significant pathophysiological implications of TRPA1 and TRPV1, eg, in pain and itch conditions, the development of selective TRPA1 and TRPV1 antagonists is being actively pursued, for instance, as novel analgesics and antipruritics. Acquiring further knowledge regarding the functional interdependency of TRPA1/ TRPV1 is therefore important for drug development, early-phase testing, and potential evaluation of disease indications.
Administration of 8% topical capsaicin (Qutenza) can drastically defunctionalize human TRPV1 1 nociceptive cutaneous afferents, 4, 9, 42, 61 thus enabling investigation of sensory and vasomotor responses in the absence of this significant proportion of nociceptors. 9, 34 This randomized, double-blinded, vehiclecontrolled study aimed to evaluate the extent of the functional overlap between the TRPA1 and TRPV1 in healthy human skin, by comparatively assessing pain, heat pain sensitivity, and neurogenic inflammation evoked by capsaicin and AITC in skin areas pretreated with topical 8% capsaicin. Based on recent rodent studies, we hypothesized that prolonged 8% capsaicin pretreatment would result in a complete abolition of TRPV1-evoked responses, but only a moderate reduction in TRPA1-evoked responses, reflecting a substantial, but incomplete, functional overlap between the 2 nociceptor populations in human skin.
Methods

Participants and study design
Eighteen healthy subjects (9M/9F, aged 27.6 6 7 years [mean 6 SD]) were recruited. Subjects were pain-free, without previous known dermatological, allergic, musculoskeletal, neurological, or psychiatric disorders. Subjects were instructed to abstain from alcohol and medications 24 hours before all sessions. Before participating in the study, all subjects signed a statement of informed consent in accordance with the 2013 Helsinki Declaration. The regional ethics committee approved the experimental protocol (study no. N-20170018). The study was conducted in a vehicle-controlled, double-blinded manner with balanced randomization of the placement of pretreatment (vehicle vs 8% capsaicin), provocation compounds (10% AITC and 1% capsaicin), and the order of provocation tests. The study was conducted in 3 sessions with intersession intervals of 24 hours (Fig. 1A) . In session 1, patches were applied; in session 2, patches were removed; and in session 3, provocation compounds were applied, and sensory as well as vasomotor responses were assessed. The investigator conducting the psychophysical tests in session 3 was blinded with respect to treatment. Therefore, investigator A conducted sessions 1 and 2, and investigator B conducted session 3 or vice versa. All sessions were conducted using a standardized script to minimize information/observer bias.
Application of 8% capsaicin and vehicle patch (pretreatment)
A total of 4 squared areas (A1-A4), measuring 4 3 4 cm, were marked on the volar forearms of all subjects (Fig. 1B) . Each area was treated in a block-randomized manner with a patch (4 3 4 cm) containing either 8% capsaicin (Qutenza; Astellas Pharma A/S, Kastrup, Denmark) or vehicle (Qutenza Demo patch; Astellas Pharma). The patches were placed 4 cm apart to blind the subjects, taking advantage of the poor spatial resolution of cutaneous chemesthesis (previously estimated to be approximately 15 cm on the longitudinal axis of the volar forearm in healthy controls) while ensuring that neurogenic inflammatory reactions evoked in the third session would not overlap. Furthermore, unblinding caused by identification of primary and secondary capsaicin-evoked neurogenic inflammation was avoided by masking patches using nontransparent medical tape. This approach has been applied in a previous study using a similar 8% capsaicin-ablation method. 9 After the application of patches in session 1, subjects rated the pain intensity on each arm, once every hour, for 6 hours. This was performed using a numerical rating scale (NRS 0-10 ; "no pain" 5 0 to "worst imaginable pain" 5 10). Then, 24 hours later, subjects rated the average and peak pain scores experienced during the 24 hours. Robust defunctionalization of TRPV1 1 epidermal fibers is known to be induced by 24-hour application of 8% capsaicin 9 ; hence, patches were left for 24 hours before being removed during session 2. After patch removal, the participants were asked whether they could identify the active patch area to get an estimate of the successfulness of the blinding procedure.
Quantitative sensory testing
In session 3, heat pain thresholds (HPTs) and suprathreshold heat pain sensitivity (SHPS) were assessed using a Medoc Pathway (Medoc Ltd, Ramat Yishay, Israel) equipped with a 3 3 3 cm stimulator probe with the aim of assessing the development of heat hyperalgesia. This was performed to assess changes in heat pain sensitivity evoked by the pretreatment and provocation compounds. All sensory tests were performed as 3 consecutive stimuli to the treated areas (A1-A4, Fig. 1B ). The provocation order and anatomical locations were randomized. Hence, if A1 was determined to be the first area for provocation compound application, this was also the first area in which sensory testing was performed. Sensory testing was performed in all 4 areas immediately before moving on to provocation compound administrations. This was performed to ensure that all measurements had the same time from pre-HPT/SHPS to substance administration (provocation).
Heat pain thresholds were measured using a ramping stimuli of 1˚C/s from a baseline temperature of 32˚C, with a cutoff of 52˚C and with 5-second interstimulus intervals based on standardized quantitative sensory testing protocols. 69, 70 As soon as the subjects sensed the warmth sensation becoming painful, they pressed a stop button resulting in a return to the baseline temperature. For SHPS, subjects verbally rated the pain intensities (same NRS 0-10 as applied for 8% capsaicin pretreatment) after each heat stimulus. A stimulus went from a 32˚C baseline to a 3-second plateau at 46˚C and with ramping of 5˚C/s. Interstimuli intervals were 10 seconds. Subjects were unable to observe the probe temperatures during the assessments. For SHPS, short 46˚C stimuli were applied to induce mild to moderate pain without evoking discernable, prolonged neurogenic inflammation (evoked around 48˚C 87 ), which could interfere with subsequent chemically evoked vasomotor responses. In addition, the stimulus intensity was chosen considering that it would be tolerable in all subjects and to avoid induction of sensitization. Although HPT is believed to be encoded predominantly by mechano-heat-sensitive C fibers ("CMH," possibly the quickly adapting subtype), the SHPS assessment was conducted to more broadly activate heat-sensitive nociceptors, including CMH, C-mechano-insensitive (CMi), and possibly type-II Ad fibers. 23, 39, 49, 84, 89 Both HPT and SHPS were calculated as mean of the 3 consecutive stimuli. ΔHPT and ΔSHPS were defined as the average difference before vs after provocations. For correlation analyses, ΔHPT 2 and ΔSHPS 2 were used, defined as the average difference between vehicle and ablated areas at baseline.
Application of chemical provocations
After the initial sensory testing, a solution containing either 10% AITC (hereafter referred to as "AITC10%") or 1% capsaicin (hereafter referred to as "CAP1%") was applied to the pretreated areas. The AITC (Sigma Aldrich, Brøndby, Denmark) was dissolved in 99% pharmaceutical grade paraffin (Løve Apoteket, Aalborg, Denmark) at a concentration of 10% AITC (vol/vol). This concentration was determined from previous studies, 48, 77 including a recently published dose-response study. 10 Capsaicin was dissolved in a solution of 30% deionized water and 70% ethanol at a concentration of 1% (10 mg/mL; Skanderborg Apotek, Denmark). For both AITC10% and CAP1%, a 50 mL solution was dispensed onto filter disk placed in a 12 mm Finn chamber attached with BSN medical tape (Fixomull Stretch; BSN Medical AB, Billdal, Sweden). Because AITC penetrates into the epidermis and evokes pain more rapidly than capsaicin, the AITC chamber was left on for 5 minutes, whereas the capsaicin chamber was left on for 20 minutes in accordance with previous studies. 48, 65 After application of provocation compounds, subjects rated the pain intensity on a digital visual analogue scale (VAS 0-100 ; "no pain" 5 0 to "worst imaginable pain" 5 100) for 6 minutes (AITC10%) or 25 minutes (CAP1%). This was performed using eVAS software (Aalborg University, Denmark) installed on a 10.10 Samsung tablet computer (Samsung Electronics, Seoul, Korea), and with pain intensity sampled at 0.2 Hz, which allowed for a continuous recording of pain intensity. The chemically evoked pain intensity was regarded as the primary outcome of the study.
Neurogenic inflammation assessed by superficial blood perfusion
Immediately after removing the Finn chambers, superficial blood perfusion was measured using a Full-Field Laser-speckle Perfusion Imaging instrument (FLPI-1; Moor Instruments Ltd, Axminster, United Kingdom). Measurements were performed at a distance of 35 cm between the FLPI lens and the skin surface. Exposure time was set to 8.3 ms and gain to 160 units. The data were analyzed using MoorFLPI Review V4.0 software (Moor Instruments Ltd). Increase in average and peak superficial blood perfusion, within the marked areas, was used as a measure of the primary neurogenic inflammation intensity. The axon-reflex-flare size, evoked by AITC10% and CAP1%, was calculated as the area exhibiting a .50% increase in superficial blood perfusion, compared with the background baseline perfusion (ie, the individual baseline capillary perfusion in areas unaffected by any skin provocation). The size was quantified in cm 2 by relative comparison with the known size of the 4 3 4 cm area, resulting in an estimate of the size of the neurogenic inflammation reaction or "axon-reflex-response." A line-approach was used to evaluate the spatial characteristics of the neurogenic inflammatory reaction. An 8 cm line, was marked longitudinally, centered through the administration area. Hereafter, superficial Heat pain thresholds and suprathreshold heat pain sensitivity (SHPS) for all areas (A1-A4) were measured before provocation, whereas assessments were made individually after each provocation. Notice that both the order of the 8% capsaicin and vehicle patches (pretreatment) and compound application (provocation) (AITC10% and capsaicin1%) were randomized. (B) Illustration of treatment areas on the volar aspects of the forearms (example). The anatomical areas were randomized with the precondition that the two CAP and AITC provocations were always conducted on the same arm. AITC, allyl isothiocyanate; CAP, capsaicin; FLPI, Full-Field Laserspeckle Perfusion Imaging; HPT, heat pain threshold; NRS, numerical rating scale (pain intensity); VAS, visual analogue scale (pain intensity). Anatomical illustrations were modified from Navigate Pain© with permission by Aglance Solutions ApS (#NP02005). perfusion along this line was quantified and averaged in 0.33 cm increments. These methods have been used in a series of previous studies. 7, 8, 10, 64 
Statistics
Data handling and calculation of descriptive statistics were performed using Microsoft Excel (Microsoft, NM), whereas statistical comparisons were performed using SPSS 25.0 (IBM, NY). Sample size estimation was conducted using the approach outlined for similar cross-over designs. 59, 64 All obtained data are presented as arithmetic mean 6 the SEM, unless otherwise stated. The collected data were tested for normality by inspecting Q-Q plots and when needed by the Shapiro-Wilk normality test. For combined reporting of statistically significant effects, the lowest F value was reported. Average and peak pain intensities (NRS and VAS recordings) were calculated and compared. The primary data analyses were conducted using repeated-measures analyses of variance (RM-ANOVAs) with the factors: pretreatment (2 levels; 8% capsaicin ablation and vehicle) and provocation (2 levels; AITC10% and CAP1%). For HPT and SHPS, an additional level of time (2 levels; before and after provocation) was added to the RM-ANOVAs. To assure that the randomized order of stimuli performed in session 3 did not constitute a bias, additional RMANOVAs were conducted wherein "order" and "anatomical location" were added as between-subject factors. Moreover, to comparatively assess the achieved inhibition of AITC and capsaicin-evoked pain, % reductions were calculated and compared using the Wilcoxon signed-rank test. Z-score changes evoked by the 8% capsaicin pretreatment were calculated allowing for cross-parameter comparisons relative to outcome variability. The formula: Z 5 ([m treatment 2 m baseline ]/s baseline ) was used. For all tests, the Bonferroni post hoc test was used to compensate for multiple comparisons. Correlational analyses between selected parameters were performed by Pearson's correlation coefficient analysis and corrected by the Holm-Sidak method. A P value #0.05 was considered significant. Asterisks for all figures: *P # 0.05, **P # 0.01, and ***P # 0.001.
Results
Nineteen subjects were enrolled and 18 completed the study sessions. One subject was excluded because of premature selfremoval of the patches due to intense pain (dropout). There were no unexpected side effects from applying either AITC or CAP. No significant differences were observed related to arm dominancy for any of the outcomes. It was specifically assessed and confirmed in all subjects that the 8% capsaicin-evoked pain had completely subsided before the beginning of session 3 (24 hours after the patch removal), which is in line with a previous study using a similar ablation technique. 9 The statistical assessment of a potential effect of provocation order, anatomical location, and interference between stimuli revealed no significant results.
Pain evoked by capsaicin-ablation treatment
During the 24-hour topical administration of 8% capsaicin patches, mean application pain plateaued at 3.8 6 0.5 (NRS 0-10 ) for the right forearm and 3.7 6 0.6 for left the forearm. There were no differences in pain between the right and left forearms (F 1,17 5 0.292, P 5 0.596). Retrospectively rated average and peak pain intensities during the 24-hour application reached 3.4 6 0.3 and 5.5 6 0.5, respectively (Fig. 2) . Subjects were able to correctly localize the active capsaicin patch site from the vehicle patch in 80.6% of the cases, with 50% being the "by chance" rate. No visible skin reaction or erythema was present when the patches were removed after 24-hour application. Hence, unblinding in a subset of participants was based purely on localization of the evoked pain during application. The subjects were not informed of which site had received the active treatment vs. the vehicle until the very end of the experiment. The subjects reported that pain subsided within 0.5 to 2 hours after removal of the patches.
Pain intensities after chemical provocations
There was a significant effect of pretreatment on both CAP1% and AITC10% mean and peak pain intensities (lowest test F value [F 1,17 5 30.9, P , 0.001; mean pain, Figs. 3A and B]). CAP1%-evoked peak pain intensity decreased from 22.7 6 4.7 (VAS 0-100 ) in vehicle-treated areas to 2 6 0.8 in ablated areas, ie, a 92.9% 6 2.5% pain reduction. The very limited CAP1%-evoked pain remaining in the ablated skin areas in 6/18 subjects indicated an almost complete defunctionalization of cutaneous capsaicinreceptiveness. For AITC, evoked peak pain decreased from 27.7 6 5.2 (VAS 0-100 ) observed in vehicle-treated areas, to 5.6 6 2.4 in ablated areas, ie, an 86.9% 6 5.0% pain reduction (Figs. 3C and  D) . Similarly, robust reductions in the ablated areas were observed for mean pain intensity (Figs. 3E and F) .
There was no main effect of provocation type for mean and peak pain (lowest test F value: F 1,17 5 1.8, P 5 0.202; peak pain), signifying that the CAP1% and AITC10% provocations evoked similar peak and mean pain intensities. Moreover, the pretreatment 3 provocation interaction was insignificant for mean and peak pain (lowest test F value: F 1,17 5 0.1, P 5 0.757; peak pain), indicating that the pretreatment-evoked desensitization inhibited subsequent CAP-and AITC-evoked pain to a similar extent. Even with isolated testing, the ablation-induced pain reductions for AITC10%-and CAP1%-exposed areas were not different (P 5 0.508).
Thermal sensory sensitivity
There was a significant interaction effect in pretreatment 3 provocation 3 time in HPT (F 1,17 5 9.4, P 5 0.007). Subsequent post hoc testing showed that capsaicin-ablated areas had significantly higher HPT (average temperature across all HPT assessments in the pretreated skin areas: 47.9 6 0.5˚C) than did vehicle-pretreated areas (average temperature across all HPT assessments in the pretreated skin areas: 40.6 6 0.6˚C, P , 0.001). This was the case both before and after provocations (P , 0.001), ie, the 24 hours of 8% capsaicin ablation established significant heat hypoalgesia even after the chemical provocations. In vehiclepretreated areas, provocation with CAP1% decreased HPT more robustly than AITC10% (P , 0.001), whereas in ablated areas, the HPT values did not differ between provocations (P 5 0.8, Fig. 4A) , constituting an antihyperalgesic effect.
A pretreatment 3 time interaction was found for SHPS (F 1,17 5 30.4, P , 0.001). Post hoc testing showed lower heat pain sensitivity in ablated areas (avg. NRS 0-10 ; [1.2 6 0.3]) than vehicle-pretreated areas (4.5 6 0.5) both before and after chemical provocations (P , 0.001), indicating heat hypoalgesia. There was a significant increase in SHPS in the vehicle areas elicited by both provocations, signifying the development of heat hyperalgesia, which did not occur in ablated areas (P , 0.001). The 8% capsaicin ablation induced an average postprovocation decrease in suprathreshold heat pain ratings of 74.9 6 7.9% for CAP1% and 74.5% 6 7.7 for AITC10% (Fig. 4B) , signifying very robust antihyperalgesic effects. The effect of eight percent capsaicin induced sensory desensitization (cap-ablation) on CAP1% and AITC10% for (C) peak, and (E) mean pain intensities. % changes (D) for peak pain and (F) for mean pain intensities after capsaicin ablation for CAP1% and AITC10%. Individual subjects (white dots) and means (gray dots). Notice that (C-F) share legends. AITC, allyl isothiocyanate; CAP, capsaicin; N.S., not significant; VAS, visual analogue scale. Means 6 SEMs are shown. ***P , 0.001. For DHPT (before vs after provocation), a pretreatment 3 provocation interaction was evident (F 1,17 5 9.4, P 5 0.007). The DHPT exhibited a significant reduction in vehicle-pretreated (25.2 6 0.7˚C) compared with ablated skin (21.0 6 0.2˚C, P , 0.001), for both types of provocations (CAP1%: P , 0.001, AITC10%: P 5 0.043). CAP1% prompted a more pronounced HPT drop than AITC10% only in vehicle-treated areas (P , 0.001, Fig. 4C ). In ablated areas, no differences were found for DHPT between provocations with CAP1% vs AITC10% (P 5 0.932). For DSHPS (before vs after provocation), there was a significant effect of pretreatment (F 1,17 5 30.4, P , 0.001). Ablated areas exhibited reduced increases in DSHPS after provocations (0.2 6 0.2) than did vehicle-pretreated areas (2.3 6 0.3, P , 0.001, Fig. 4D ). For DSHPS, there were no differences between the 2 types of provocations (P 5 0.534).
Neurogenic inflammatory response
A pretreatment 3 provocation interaction was found for both mean and peak perfusion (lowest test F value: F 1,17 5 4.861, P 5 0.042, mean perfusion). In ablated areas, no significant differences were found between provocations (mean P 5 0.435, peak P 5 0.183), corresponding to almost entirely indiscernible reactions in most subjects (Fig. 5) . In vehicle areas, CAP1% produced a significantly larger increase in both mean and peak perfusion compared with AITC10% (mean P 5 0.023, peak P 5 0.021). For axon-reflex-flare, there was a significant effect of pretreatment (F 1,17 5 141.7, P , 0.001). The capsaicin ablation caused a decrease in flare size from 7.5 6 0.7 cm 2 in vehicletreated areas to 0.5 6 0.5 cm 2 in ablated areas for CAP1% and similarly for AITC10% from 8.0 6 0.8 to 0.5 6 0.4 cm 2 (P , 0.001, Figs. 6A and B) . No significant effect of provocation was found on axon-reflex-flare size (F 1,17 5 0.213, P 5 0.650), suggesting that the AITC10% and the CAP1% provocations evoked comparable neurogenic inflammatory responses. The line analysis (Fig. 6C) did not reveal any significant differences in the spatial distribution of the neurogenic inflammatory reaction, in neither the vehicle-nor capsaicin-ablated areas. However, a trend towards a more dispersed, but less homotopically intense AITC10%-induced neurogenic flare was evident (smallest P 5 0.11). Similarly, an insignificant trend towards slightly increased perfusion was observed for AITC10% in capsaicinablated areas restricted only to the provocation administration area (Fig. 6C) . Heat pain sensitivity before and after provocation by CAP1% and AITC10% in vehicle-and capsaicin-ablated areas. (A) Heat pain thresholds in capsaicin-ablated (gray) and vehicle-pretreated (white) skin area for both CAP1% and AITC10%. (B) Suprathreshold heat pain sensitivity in capsaicin-ablated (gray) and vehicle-pretreated (white) skin area for both CAP1% and AITC10%. (C) Change in HPT after application of CAP1% and AITC10%. (D) Change in SHPS after application of CAP1% and AITC10%. AITC, allyl isothiocyanate; CAP, capsaicin; HPT, heat pain threshold; NRS, numerical rating scale; N.S., not significant; SHPS, suprathreshold heat pain sensitivity. Means 6 SEMs are shown (A and B) and means are shown (C and D). **P , 0.01 and ***P , 0.001.
Sex-related differences
For peak pain, an interaction effect was found between pretreatment 3 provocation 3 sex (F 1,16 5 4,7, P 5 0.045). Subsequent post hoc showed that females had significantly higher peak pain scores in vehicle-pretreated areas after CAP1% application (34.2 6 7.3, VAS 0-100 ) than did males (11.2 6 2.6, P 5 0.009). This was not the case for AITC10% (P 5 0.350). For mean perfusion, a pretreatment 3 sex interaction was found (F 2,16 5 4.703, P 5 0.046). Post hoc tests showed that in female subjects, vehicle-pretreated areas exhibited a higher increase in mean perfusion as compared to that of male subjects. This was true both for CAP1% (P 5 0.007) and to a lesser extent for AITC10%-induced reactions (P 5 0.05). Representative superficial blood perfusion readouts. Four images from 5 different subjects after provocation by CAP1% and AITC10% in vehicle-and capsaicin-ablated skin areas. Notice the almost complete inhibition of neurogenic inflammation in capsaicin-ablated areas, with only very slight increases in perfusion corresponding to the Finn chamber application area in 2 subjects shown in the upper panels. The black quadrant in lower left corner marks the assessment area, whereas the black circle marks the provocation administration area. AITC, allyl isothiocyanate (10%); arb., arbitrary; CAP, capsaicin (1%). 
Correlations
A positive correlation was found between 8% capsaicin-ablationevoked pain and CAP1%-evoked pain in the vehicle-pretreated skin (r 5 0.676, P 5 0.027, Table 1 ). Similarly, both 8% capsaicin-ablation-evoked pain and CAP1%-evoked pain correlated strongly with baseline SHPS (lowest: r 5 0.702, P 5 0.001), which was not the case for AITC10%-evoked pain and SHPS (P 5 0.29). No significant correlation was found between mean capsaicin-ablation-evoked pain (24 hours) and the obtained difference between SHPS in vehicle and ablated areas at baseline (DSHPS 2 , r 5 0.577, P 5 0.094). In vehicle areas, a strong positive correlation was found for neurogenic flare between CAP1% and AITC10% (mean r 5 0.756, P , 0.001, peak r 5 0.704, P 5 0.001). No correlation was found between AITC10%-evoked pain vs heat pain sensitivity or CAP1%-evoked pain (r 5 0.475, P 5 0.282), suggesting that sensitivity to provocations by CAP1% or heat stimuli does not confer sensitivity to AITC10%.
Z-scores
Fig . 7 provides a comparative overview of the capsaicinablation-evoked changes when accounting for the natural variability within each parameter. When assessing the efficacy of the different sensory and vasomotor responses for CAP1%, the inhibition of heat hyperalgesia (DHPT) showed the most decreased z-score, indicating that this parameter most robustly detected the ablation responses. Notice that compared with AITC10%, this effect of the ablation was exclusively driven by CAP1%'s more robust elicitation of heat hyperalgesia (as Table 1 Correlational analysis.
Significant correlations are marked in grey. P values are multiplicity corrected by the Holm-Sidak method. An isolated correlational analysis of mean perfusion data was performed to retain power. *P , 0.05, **P , 0.01, and ***P , 0.001. A, ablated area; AITC, allyl isothiocyanate; CAP, capsaicin; SHPS, suprathreshold heat pain sensitivity; V, vehicle area. assessed by HPT) in the vehicle-pretreated areas. For AITC10%, changes in mean axon-reflex-flare size exhibited the most decreased z-score and this parameter was also the second most robustly decreased for CAP1%.
Discussion
High-concentration capsaicin ablation almost completely abolished both AITC-and capsaicin-evoked pain, heat hyperalgesia, and neurogenic inflammation. For both AITC10% (TRPA1 agonist) and CAP1% (TRPV1 agonist) provocations, the evoked pain intensities were reduced to the same extent by around 90% by the ablation of capsaicin-sensitive nociceptors. Hence, no differences in the desensitization efficacy of the capsaicin ablation were observed for the 2 different nociceptive TRP provocations, suggesting that TRPA1 nociceptors in human skin are uniformly capsaicin-sensitive.
Capsaicin ablation
Topical high-concentration capsaicin causes defunctionalization of capsaicin-sensitive fibers resulting in profound reduction of contact and laser-evoked heat pain sensitivity 9, 34, 42, 54, 61 properties ascribed to the function of superficial TRPV1
1 nociceptors. 4, 21, 62 It is unclear whether nociceptor activation per se is a crucial aspect of this desensitization process. Some clinical studies have asserted that the use of local anesthetics do not reduce the efficacy of the capsaicin ablation. 43, 68, 83 However, experimental studies have found an association between the pain experienced during patch application and the efficacy of the desensitization. 9, 57, 79 This study did not show a positive correlation between capsaicin-ablation-induced pain and ΔSHPS 2 (difference between vehicle and ablated areas), although a trend was evident (corrected P 5 0.09), suggesting that the vigorousness of the nociceptive barrage during the ablation and the resultant desensitization are not strictly aligned.
Capsaicin 8% pretreatment inhibits both TRPV1-and TRPA1-evoked responses
Previous studies using similar chemical provocation techniques have found pain intensity curves and neurogenic inflammation for both AITC and capsaicin, which were comparable with the present findings. 10, 48, 65, 77 Currently, profound reductions in both mean and peak pain were seen in capsaicin-ablated areas when subsequently exposed to AITC10% or CAP1% with no significant differences between the 2 provocations. This suggests that the defunctionalization of TRPV1-expressing cutaneous fibers robustly abolishes TRPA1-evoked nociceptive responses and implies that no functionally significant subpopulation of nociceptors in human skin is TRPA1 1 /TRPV1 2 . These functional human data support animal studies suggesting that TRPA1 receptors are almost completely coexpressed with TRPV1 receptors 40, 45, 81 (see section 4.3). Strong correlations were present between heat pain sensitivity and capsaicin-evoked pain in vehicle-treated areas. On the contrary, a complete lack of correlations was observed between AITC-evoked pain and heat or/capsaicinevoked pain. With our main conclusion in mind, AITC thus produces pain in a distinct manner compared with heat or capsaicin. Because the prolonged capsaicin pretreatment is believed to defunctionalize and ablate fiber branches and this practically abolished AITC reactivity, it is corroborated psychophysically that AITC-evoked pain is distinct at the receptor level (ie, engaging TRPA1), whereas it seems to rely on TRPV1-coexpressing fibers.
Mechanistically, the development of primary heat hyperalgesia involves sensitization of both Ad and C fibers, 78 and it is well documented to occur after topical application of capsaicin 61 and AITC. 10, 77 Notably, and distinct from, eg, allodynia, primary heat hyperalgesia can be evoked without spontaneous preceding or ongoing pain (eg, after ultraviolet B irradiation). 34 In this study, both short-term topical AITC10% and CAP1% provocations generated substantial heat hyperalgesia in the vehicle-pretreated skin. However, after a prolonged high-concentration capsaicin ablation, the development of heat hyperalgesia was entirely abolished and replaced by stabile heat hypoalgesia. This signifies that no sensitization of heat-sensitive nociceptors occurred and that no sensitization of a potential heat-insensitive TRPA1
1
/TRPV1
2 nociceptor subpopulation resulted in de novo heat pain receptiveness after the chemical provocations. In this context, it has been suggested that rodent TRPV1
2 heat-insensitive nociceptors may develop heat pain sensitivity during partially TRPA1-mediated inflammation, 30 but these fibers alone are insufficient for the establishment of heat hyperalgesia. 46 This notion is aligned with the results of the present study. It is very likely that TRPA1-mediated heat hyperalgesia is caused by peripheral sensitization of nerve fibers coexpressing TRPV1, although the exact molecular mechanism(s) for such heat sensitization is unclear. 26, 35, 86 Presently, the defunctionalization of such nerves markedly inhibited the heat hyperalgesic effect of AITC. The stronger heat hyperalgesia observed for HPT in the vehicle-pretreated skin after CAP1% application could signify preferential effect on a subset of heat-sensitive nociceptors, which express TRPV1, but not TRPA1. Based on evidence from primate microneurography, it could be speculated that the drastic HPT decreases observed in the vehicle-pretreated skin following CAP1% are mediated predominantly by CMH fibers, whereas a more considerable contribution from additional sensitized heatnociceptor populations likely contributes to the elevated SHPS. 23, 39, 49, 84, 89 After ablation, essentially all heat-sensitive units (CMH, CMi, and Ad fibers) responsive in the TRPV1 activation range would be defunctionalized and thus, the heat pain sensitivity diminishes (HPT and SHPS) and no heat hyperalgesia can be mounted after AITC10% or CAP1%.
The axon-reflex-flare response is mediated predominantly by CMi fibers through release of vasoactive peptides. [73] [74] [75] In the vehicle-pretreated skin, AITC10% and CAP1% induced similar neurogenic flare reactions suggesting that the same substrate is engaged by both provocations and that differences in transdermal penetration were reasonably well accounted for. At the receptor level, AITC has been shown to induce neurogenic inflammation in a TRPV1-independent manner in rodents assessed by acute plasma extravasation. 15 However, there are notable differences between neurogenic inflammatory characteristics in rodent vs human skin (where plasma extravasation generally does no occur). 75 Presently, the 24-hour capsaicin ablation resulted in an almost complete inhibition of the axonreflex-flare and robustly reduced increases in mean and peak perfusion after chemical provocations. The inhibitory effect of capsaicin-induced defunctionalization on neurogenic flare evoked by various irritants is well established. 25, 32, 34, 55, 73 As the inhibition of the axon-reflex-flare caused by the ablation was similar for both areas treated with CAP1% and AITC10%, the induced flares presumably depend entirely on TRPA1
1 /TRPV1 40 Similar findings have been reported in several studies. 18, 45 Contrasting these initial studies, Malin et al. 56 demonstrated that skin afferents express TRPV1, TRPA1, or both more rarely than previously assumed, ie, 22% expressed TRPV1 mRNA, 6% expressed TRPA1, but only 10% expressed both TRPV1 and TRPA1. Another study in mice DRG neurons showed that 49.7% of units expressed TRPV1, 43% TRPA1, but only 99 out of 149 TRPA1
1 neurons coexpressed TRPV1, 82 which is aligned approximately with recent results from rat trigeminal neurons. 36 Finally, RNA sequencing in mice DRG neurons has shown a subpopulation of nociceptors expressing TRPA1 and MrgprD, but not TRPV1. 85, 90 Distinct innervation of various tissues and differences in DRG and axonal mRNA expression may, in part, explain the contradictory findings. 24, 56 This study used a capsaicin-ablation intervention to estimate the functional coexpression of TRPA1 and TRPV1 in human epidermal nerve fibers and findings support the notion of TRPA1 being expressed in a subset of TRPV1 1 fibers as described in early rodent studies. In this context, it should be highlighted that substantial interspecies differences are well documented within somatosensory afferent neurophysiology and transducer expression. 29, 52 This study adds information about the interdependency of TRPA1-and TRPV1-evoked responses in humans, where previous evidence is scarce. In vitro responses of sensory neurons indicate transient homologous and heterologous desensitization mechanisms for TRPA1 and TRPV1 when stimulated with AITC and capsaicin, 1 whereas some in vivo data contradict this notion. 15 Data by Simons et al. 80 using administration to the oral mucosa of capsaicin and AITC in humans also suggested rapid self-and cross-desensitization between the 2 agonists. However, AITC-evoked responses after a prolonged capsaicin-induced desensitization have not previously been studied in humans, and TRPA1 agonists do not seem to induce desensitization in human skin. The discrepancies between data from the oral mucosa and skin probably are related to different study designs, including diverse concentrations and exposure times, as well as tissue-related differences in, eg, sensory sensitivity, penetration, and clearance (all of which are remarkably higher in the oral mucosa compared with the skin). Notably, many of the pain and itch conditions where TRPA1 and TRPV1 antagonists have been proposed to be of potential clinical utility involve the skin and the cutaneous afferents (eg, inflammatory skin diseases and peripheral neuropathies 12, 30, 33, 47 ).
Clinical implications
The development of systemic and topical antagonists for TRPA1 and TRPV1 is currently ongoing and several lead compounds have been, and are being, tested in clinical trials. 41, 58, 66 The efficacy of selective TRP antagonists has unfortunately so far not shown strong clinical effects in chronic pain and, eg, TRPV1 antagonists have shown considerable adverse effects such as hyperthermia. 58 To account for the redundancy associated with nociceptive transduction in the periphery and to achieve better efficacy, developing dual TRP antagonists (eg, targeting both TRPV1 and TRPA1) might be a viable option. Just as selective activation of TRPV1 and TRPA1 is performed in animal drug profiling studies, it is possible to test, eg, TRPA1 antagonists for effect and target engagement in early clinical drug trials, 13, 33 but this requires reliable provocation models. The profound responsiveness observed for FLPI-measured neurogenic inflammation supports monitoring this outcome in response to TRPA1 or TRPV1 agonist provocations as a suitable and sensitive target engagement biomarker in humans. 13, 20, 33 Chemical activation of TRPV1 and TRPA1 may also be used for sensory profiling purposes in patients with, eg, peripheral neuropathic pain conditions and adds to the existing quantitative sensory testing platforms as a way to translate preclinical findings into patients. 16 Such receptor profiling may provide additional information on loss-or gain-of-function for these specific receptor populations, and similar mechanistic phenotyping has been shown to predict the effect of certain analgesics. 27 The current receptor-specific provocation models may also be used for testing, eg, novel TRPA1 antagonists and recently clinical studies have been initiated provoking TRPA1/TRPV1 responses in patients with, for instance, allergies or inflammatory dermatoses, to investigate itch, pain, and inflammatory responses.
2,5,6,38
Limitations and future perspectives
Although topical high-concentration capsaicin could potentially evoke effects on non-neuronal tissues, such as endothelial cells or unspecifically desensitize nerve terminals independently of TRPV1, for instance, through mitochondrial respiratory distress or off-target effects related to the induced inflammation, such effects are probably marginal. TRPA1 modulation by inflammation generally seems to enhance TRPA1 expression and function, 30, 37, 60 whereas capsaicin-induced ablation is believed to rely on Ca 21 -influx overload through TRPV1 as well as mismatch between high-energy expenditure (given the prolonged vigorous firing induced by TRPV1 activation coupled with dysfunctional mitochondrial metabolism). 4, 62 This relative TRPV1 specificity of the applied ablation is supported by the fact that no lingering inflammation is present when 8% capsaicin patches are removed, and the endothelial reactivity assessed by wheal responsiveness (an entirely non-neurogenic reflex) is normal in the ablated skin. 9 Moreover, psychophysical evidence suggests that only warmth and heat sensitivity are very robustly decreased in the skin after 8% capsaicin pretreatment. 34, 51, 54 The fact that unblinding occurred in a subset of subjects has limited impact on the interpretation of the results both because testing occurred 24 hours after identification (which was never revealed to the subject) but also because the primary analyses simply compared the achieved relative inhibition between the 2 chemical provocations. A key premise was TRPV1 and TRPA1 activation by capsaicin and AITC, respectively. The selectivity of the 2 TRP agonists, AITC in particular, has been questioned, 3, 31, 56 but overall, a large amount of evidence support their relative specificity. 11, 14, 17, 40, 53, 71 More importantly, in this context, even if a proportion of the nociceptive response of AITC was mediated by direct TRPV1 activation, the basic result interpretation would have remained unchanged. Similarly, even if prolonged capsaicin exposure causes heterologous desensitization of TRPA1 channels this would still only apply to fibers expressing TRPV1 and would thus leave a potential population of TRPV1 2 /TRPA1 1 fibers unaffected. Because a robust correlation was present between SHPS or HPT and CAP1%-induced pain but not AITC10% pain, such unspecific AITC-engagement of TRPV1 seems unlikely. Finally, this study did not assess to which extent capsaicin sensitivity is maintained after a TRPA1-associated nerve fiber defunctionalization and thus cannot evaluate the significance and function of TRPV1 1 , but TRPA1 2 cutaneous nociceptors. Such a subpopulation is uniformly reported in rodents and likely exists in human skin. 45, 85 Unfortunately, a parallel method for TRPA1-associated fiber defunctionalization in human skin does not yet exist and prolonged topical application of TRPA1 agonists is generally associated with more prolonged and extensive skin inflammation than TRPV1 agonists. 10 
Conclusion
Ablation of capsaicin-sensitive cutaneous fibers using highconcentration capsaicin strongly inhibited both AITC and capsaicin-evoked responses, including spontaneous pain, heat hyperalgesia, and neurogenic inflammation. The inhibition was consistent across all parameters and of similar efficaciousness for both chemical provocations. Thus, normal nociceptive AITC responses are robustly inhibited when capsaicin-sensitive cutaneous nerve fibers are defunctionalized. This suggests that in human skin, TRPA1
1 primary cutaneous afferents belong to a subpopulation of TRPV1 1 nociceptors.
